Related Experiment Videos

The role of Beta-blockers as first-line therapy in hypertension

Alberto Ranieri De Caterina1, Antonio Maria Leone

  • 1Institute of Cardiology, Catholic University of the Sacred Heart, Policlinico A. Gemelli, Largo A. Gemelli, 8, 00168, Rome, Italy. adecatro@yahoo.it

Current Atherosclerosis Reports
|January 6, 2011
PubMed

Insights

Beta-blockers (BBs) are not recommended as first-line hypertension treatment due to less effective blood pressure reduction and poorer cardiovascular outcomes compared to other drugs. Evidence suggests BBs may increase stroke risk and are linked to worse overall cardiovascular prognosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Current guidelines recommend beta-blockers (BBs) for uncomplicated hypertension prevention.
  • However, BBs demonstrate reduced efficacy in lowering blood pressure, particularly central aortic pressure, compared to alternative antihypertensives.

Purpose of the Study:

  • To evaluate the efficacy and safety of beta-blockers (BBs) as first-line agents for hypertension management.
  • To assess the impact of BBs on cardiovascular outcomes, including stroke risk and overall prognosis.

Main Methods:

  • Review of national and international guidelines.
  • Analysis of recent meta-analyses comparing BBs with placebo and other antihypertensive drug classes.
  • Consideration of factors influencing BBs' cardioprotective effects.

Main Results:

  • BBs show weaker effects on blood pressure reduction compared to other agents.
  • Meta-analyses indicate a limited benefit of BBs in stroke prevention and potentially worse cardiovascular outcomes.
  • Factors like unfavorable metabolic profiles and lack of efficacy on left ventricular hypertrophy contribute to their mild cardioprotective effects.

Conclusions:

  • Available evidence does not support the use of BBs as first-line therapy for uncomplicated hypertension.
  • Further research is needed to determine if newer BBs like nebivolol and carvedilol offer improved cardiovascular outcomes compared to older agents.

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...